Medicare Beneficiaries Will Pay Just $50/Month for Zepbound Under New Lilly Deal — Starting April 2026

In a move that could reshape the landscape of obesity treatment for America's seniors, Eli Lilly and the federal government have announced a landmark agreement to dramatically expand access to Zepbound (tirzepatide) for Medicare beneficiaries. Starting as early as April 1, 2026, seniors enrolled in Medicare will pay no more than $50 per month for Zepbound — available in a convenient multi-dose pen format.

This represents one of the most significant reductions in GLP-1 medication costs in the history of the obesity treatment market. For context, the current list price for Zepbound exceeds $1,000 per month, and even with manufacturer savings cards, many Medicare beneficiaries have faced out-of-pocket costs of $400-$600 or more per month — if their plan covered the medication at all.

Why This Deal Matters Right Now

The timing of this announcement is notable. Just weeks ago, the FDA officially ended the nearly three-year semaglutide shortage, confirming that Novo Nordisk is now meeting or exceeding demand for Wegovy and Ozempic. That resolution came with a significant catch: the end of the shortage also signaled the beginning of the end for the compounded GLP-1 industry, with the FDA giving pharmacies 90 days to cease producing unapproved versions of tirzepatide and semaglutide.

For millions of patients who had relied on compounded GLP-1s as a more affordable alternative — typically $150-$300/month — the transition to brand-name medications was looking increasingly expensive. The Lilly-Medicare deal directly addresses that concern, potentially making brand-name Zepbound cheaper than what many patients were paying for compounded versions.

"This is a watershed moment for obesity treatment access in America," said Dr. Amanda Reyes, an endocrinologist at Johns Hopkins Medicine. "For too long, Medicare beneficiaries have been effectively locked out of the most effective obesity medications due to cost. A $50 monthly copay changes the calculus entirely."

Who Qualifies and How It Works

The $50/month pricing applies to Medicare beneficiaries who have a prescription for Zepbound and whose plan has opted into the agreement. According to the terms announced, patients will receive Zepbound through a multi-dose pen, which differs from the single-dose auto-injector currently available commercially.

The key eligibility points:

• Medicare Part D enrollment: Patients must be enrolled in a Medicare Part D plan that has opted into the agreement
• Obesity diagnosis: A body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity
• Prior authorization: As with all GLP-1 medications under Medicare, prior authorization will likely be required

Not all Medicare plans have committed to offering the $50 pricing as of yet. Patients should contact their Part D plan directly to confirm whether they'll be offering the reduced copay and what the enrollment process looks like.

How This Compares to Other GLP-1 Access Pathways

The $50/month Medicare price positions Zepbound competitively against other GLP-1 access options now available:

TrumpRx: The TrumpRx program, launched earlier this year, offers Zepbound at approximately $346/month for uninsured patients. The Medicare deal actually undercuts this, making it the new lowest-cost pathway for tirzepatide access.

GoodRx Telemedicine: GoodRx's recently launched oral semaglutide service offers pricing from $149-$299/month, depending on dose. The Medicare Zepbound deal remains competitive against this.

Manufacturer Savings Programs: Lilly's traditional savings card programs can reduce costs for commercially insured patients, but these programs have historically been more limited for Medicare beneficiaries due to federal anti-kickback restrictions.

What This Means for the GLP-1 Market

The Lilly-Medicare deal is being widely interpreted as a strategic response to several converging market pressures:

Competition from compounded GLP-1s: The compounded GLP-1 industry, which served millions of cash-pay patients at lower prices, is now facing imminent shutdown. By offering a $50/month option through Medicare, Lilly positions brand-name Zepbound as the logical replacement.

Political pressure: Both the Trump administration and Congress have increasingly pressured pharmaceutical companies to expand GLP-1 access, particularly for seniors and other vulnerable populations. This deal can be seen as proactive regulatory relationship management.

Market share defense: With Novo Nordisk's Wegovy now widely available following the end of the semaglutide shortage, and oral semaglutide gaining rapid adoption, Lilly needed a competitive response. The Medicare deal gives Zepbound a significant pricing advantage in a key demographic.

What Patients Should Do Now

If you're a Medicare beneficiary currently taking a GLP-1 medication — or considering starting one — here's your action plan:

1. Contact your Medicare Part D plan. Ask specifically whether they'll be offering the $50/month Zepbound copay and what the enrollment requirements are.

2. Talk to your doctor. If you've been considering GLP-1 treatment but were deterred by cost, this is the time to revisit that conversation. The economics have fundamentally changed.

3. If you're currently on compounded tirzepatide: This deal strengthens the case for transitioning to brand-name Zepbound before the 90-day FDA deadline expires. Your total cost may actually go down.

4. Consider all options: If your Part D plan isn't offering the $50 pricing, ask about TrumpRx or other manufacturer programs. Some patients may still save money through alternative pathways.

Looking Ahead

The $50/month Medicare pricing for Zepbound represents the most significant GLP-1 access expansion in the program's history. Whether similar deals emerge for other GLP-1 medications — or whether this model extends beyond Medicare to commercial insurance — remains to be seen. But for millions of obese Americans on Medicare, April 2026 marks a turning point.

The message from the industry is clear: the era of $1,000/month GLP-1 medications may be ending, replaced by a new reality of broader access at sustainable prices. For patients, that future arrived earlier than many expected.

Will Medicare cover Zepbound for weight loss?

Medicare Part D historically has not covered obesity medications as a primary indication. However, the Lilly deal represents a negotiated agreement that may override some traditional coverage limitations. Patients should check with their specific Part D plan for coverage details.

Does this apply to Mounjaro (tirzepatide for diabetes)?

The announced deal specifically mentions Zepbound for obesity. Mounjaro, which contains the same active ingredient (tirzepatide) but is approved for type 2 diabetes, may have different pricing and coverage terms. Patients with diabetes should consult their plan for specific medication pricing.

Can I switch from Wegovy to Zepbound under this deal?

Patients working with their healthcare provider can discuss whether transitioning from semaglutide (Wegovy) to tirzepatide (Zepbound) makes sense for their situation. Both are highly effective GLP-1 medications, and the $50/month Medicare pricing applies to Zepbound specifically.